OxOnc Development LP Report issue

For profit Phase 2
Founded: Princeton NJ United States (2012)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2013
NCT01945021
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

crizotinib (xalkori) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1